BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 6:27:00 PM | Browse: 1039 | Download: 945
 |
Received |
|
2013-12-08 12:41 |
 |
Peer-Review Started |
|
2013-12-08 13:39 |
 |
To Make the First Decision |
|
2014-01-16 08:15 |
 |
Return for Revision |
|
2014-01-17 12:07 |
 |
Revised |
|
|
 |
Second Decision |
|
2014-02-19 11:13 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-02-19 11:36 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-04-18 17:56 |
 |
Publish the Manuscript Online |
|
2014-04-28 14:14 |
Category |
Cell Biology |
Manuscript Type |
Minireviews |
Article Title |
Familial Alzheimer’s disease modelling using induced pluripotent stem cell technology
|
Manuscript Source |
Invited Manuscript |
All Author List |
Lisa Mohamet, Natalie J Miazga and Christopher M Ward |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
United Kingdom Biotechnology and Biosciences Research Council |
|
Engineering and Physical Sciences Research Council and the Technology Strategy Board |
|
|
Corresponding Author |
Dr. Christopher M Ward, Stem Cell Biology Group, Core Technology Facility, Faculty of Human and Medical Sciences, The University of Manchester, Manchester, 46 Grafton Street, Manchester M13 9NT, United Kingdom. christopher.ward@manchester.ac.uk |
Key Words |
Human induced pluripotent stem cells; Alzheimer’s disease; Neurodegenerative diseases; High-throughput screening assays; Cholinergic neurons; Drug discovery; Stratified medicine |
Core Tip |
Alzheimer’s disease (AD) affects 36 million people worldwide and is set to double by 2030. Progress in understanding AD has been hindered by a lack of suitable in vitro and in vivo models reflected in > 90% drug attrition rates. Induced pluripotent stem cells are an alternative source of neural cells that can be derived from patients’ somatic cells and exhibit AD pathophysiological phenotypes. These cells are amenable to HTS formats required for drug discovery applications. Harnessing this combined potential would provide an unprecedented opportunity to significantly reduce timeframes and costs associated with developing novel therapeutics, ultimately improving patient outcomes. |
Publish Date |
2014-04-28 14:14 |
Citation |
Mohamet L, Miazga NJ, Ward CM. Familial Alzheimer’s disease modelling using induced pluripotent stem cell technology. World J Stem Cells 2014; 6(2): 239-247 |
URL |
http://www.wjgnet.com/1948-0210/full/v6/i2/239.htm |
DOI |
http://dx.doi.org/10.4252/wjsc.v6.i2.239 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345